Triple negative breast cancer is the most aggressive type of breast cancer affecting women, and there are currently very few therapeutic options for the treatment of this disease. This is largely due to the heterogeneity of triple negative breast cancer and a lack of in-depth understanding of the regulatory factors controlling triple negative tumour progression. The aim of this proposal is to use a novel mass spectrometry-based approach to identify key Transcriptional regulators of tumour growth in multiple triple negative breast cancer subtypes. This will allow us to understand triple negative breast cancer heterogeneity at the transcriptional level, and it will form the basis for identifying potential therapeutic targets in this disease. Insights from this proposal will also build the foundation for future research into triple negative breast cancer biology in my lab at the University of Southern Denmark.
|Effective start/end date||01/09/2019 → 31/08/2021|